Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug4493 | Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 5 Wiki | 1.00 |
drug4492 | Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 3 Wiki | 1.00 |
drug4496 | Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 3 Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D065631 | Rhinitis, Allergic NIH | 1.00 |
D006255 | Rhinitis, Allergic, Seasonal NIH | 1.00 |
D012220 | Rhinitis, NIH | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0012395 | Seasonal allergy HPO | 1.00 |
HP:0012384 | Rhinitis HPO | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
This study is to assess the onset of action of fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray (Dymista) in treating the nasal symptoms of seasonal allergic rhinitis (SAR) induced by an allergen challenge in an Environmental Exposure Unit (EEU).
Description: The sum of the TNSS will contribute to a score ranging from 0 - 12
Measure: Time to onset of action, measured by a difference from placebo in the change from baseline in patient -assessed instantaneous Total nasal symptom score (TNSS) following treatment Time: 0 to 4 hours post applicationDescription: The sum of the TOSS will contribute to a score ranging from 0 - 9.
Measure: Time to onset of action, measured by a difference from placebo in the change from baseline in patient-assessed instantaneous total ocular symptom score (TOSS) following treatment Time: 0 to 4 hours post applicationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports